{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '14', 'ADDITIONAL REQUIREMENTS', '14.1 CURRICULUM VITAE', 'A current copy of the curriculum vitae describing the experience, qualification and training of', 'each Investigator and Sub-investigator will be signed, dated and provided to the Sponsor prior to', 'the beginning of the clinical trial.', '14.2 RECORD RETENTION IN STUDY SITES', 'The Investigator must maintain confidential all study documentation, and take measures to', 'prevent accidental or premature destruction of these documents.', 'The Investigator should retain the study documents at least 15 years after the completion or', 'discontinuation of the clinical trial.', 'However, applicable regulatory requirements should be taken into account in the event that a', 'longer period is required.', 'The Investigator must notify the Sponsor prior to destroying any study essential documents', 'following the clinical trial completion or discontinuation.', \"If the Investigator's personal situation is such that archiving can no longer be ensured by him/her,\", 'the Investigator shall inform the Sponsor and the relevant records shall be transferred to a', 'mutually agreed upon designee.', '14.3 CONFIDENTIALITY', 'All information disclosed or provided by the Sponsor (or any company/institution acting on their', 'behalf), or produced during the clinical trial, including, but not limited to, the clinical trial', \"protocol, personal data in relation to the patients, the e-CRFs, the Investigator's Brochure and the\", 'results obtained during the course of the clinical trial, is confidential, prior to the publication of', 'results. The Investigator and any person under his/her authority agree to undertake to keep', 'confidential and not to disclose the information to any third party without the prior written', 'approval of the Sponsor.', 'However, the submission of this clinical trial protocol and other necessary documentation to the', 'EC (IRB/IEC) is expressly permitted, the IRB/IEC members having the same obligation of', 'confidentiality.', 'The Sub-investigators shall be bound by the same obligation as the Investigator. The Investigator', 'shall inform the Sub-investigators of the confidential nature of the clinical trial.', 'The Investigator and the Sub-investigators shall use the information solely for the purposes of the', \"clinical trial, to the exclusion of any use for their own or for a third party's account.\", 'Property of the Sanofi Group - strictly confidential', 'Page 128', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '14.4 PROPERTY RIGHTS', 'All information, documents and IMP provided by the Sponsor or its designee are and remain the', 'sole property of the Sponsor.', 'The Investigator shall not and shall cause the delegated Investigator staff/Sub-investigator not to', 'mention any information or the Product in any application for a patent or for any other intellectual', 'property rights.', 'All the results, data, documents and inventions, which arise directly or indirectly from the clinical', 'trial in any form, shall be the immediate and exclusive property of the Sponsor.', 'The Sponsor may use or exploit all the results at its own discretion, without any limitation to its', 'property right (territory, field, continuance). The Sponsor shall be under no obligation to patent,', 'develop, market or otherwise use the results of the clinical trial.', 'As the case may be, the Investigator and/or the Sub-investigators shall provide all assistance', \"required by the Sponsor, at the Sponsor's expense, for obtaining and defending any patent,\", 'including signature of legal documents.', '14.5', 'DATA PROTECTION', \"The patient's personal data, which are included in the Sponsor database shall be treated in\", 'compliance with all applicable laws and regulations', 'When archiving or processing personal data pertaining to the Investigator and/or to the', 'patients, the Sponsor shall take all appropriate measures to safeguard and prevent access to', 'this data by any unauthorized third party', 'The Sponsor also collects specific data regarding Investigator as well as personal data', \"from any person involved in the study which may be included in the Sponsor's databases,\", 'shall be treated by both the Sponsor and the Investigator in compliance with all applicable', 'laws and regulations', 'Subject race or ethnicity will be collected in this study because these data are required by several', 'regulatory authorities (eg, on African American population for FDA).', 'Analyses of subject genetic data will be conducted as described in the protocol as this is needed', 'for pharmacogenetics analyses required for the purposes of the study or by regulatory authorities.', 'The data collected in this study will only be used for the purpose(s) of the study and to document', 'the evaluation of the benefit/risk ratio, efficacy, and safety of the product(s) They may be further', 'processed if they have been anonymized.', '14.6 INSURANCE COMPENSATION', 'The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials', 'under its sponsorship. This insurance policy is in accordance with local laws and requirements.', 'Property of the Sanofi Group - strictly confidential', 'Page 129', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}